Next Article in Journal / Special Issue
Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
Previous Article in Journal
Utility of Direct Fast Scarlet Staining in the Histopathological Diagnosis of Eosinophilic Esophagitis: A Short Report
Previous Article in Special Issue
Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing
Article

Ureteral Stent and Percutaneous Nephrostomy in Managing Malignant Ureteric Obstruction of Gastrointestinal Origin: A 10 Years’ Experience

1
Urology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
2
Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
3
Division of Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Gastrointest. Disord. 2020, 2(4), 456-468; https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040041
Received: 31 October 2020 / Revised: 26 November 2020 / Accepted: 2 December 2020 / Published: 8 December 2020
Background: Malignant ureteral obstruction (MUO) is variable in presentation and there is no consensus on its management, especially when caused by gastrointestinal (GI) malignancies. Our aim was to describe our experience with this oncological complication. Methods: We retrospectively analyzed the outcomes of ureteral stent and nephrostomy tube (NT) positioning for GI-related MUO from 2010 to 2020. We performed descriptive analysis, survival analysis, and uni- and multi-variate analysis. Results: We included 51 patients. NT was mainly used when bladder involvement occurred and when MUO revealed an ex novo cancer diagnosis. Survival was poorer in patients with new diagnoses and in those receiving no treatment after decompression. Moreover, MUO caused by upper-GI tumors was related to shorter overall survival. Conclusions: GI tumors causing MUO should be considered of poor prognosis. Treatment decisions should be weighted accurately by both specialists and the patient. View Full-Text
Keywords: ureteral obstruction; gastrointestinal cancer; percutaneous nephrostomy; decompression ureteral obstruction; gastrointestinal cancer; percutaneous nephrostomy; decompression
Show Figures

Figure 1

MDPI and ACS Style

De Lorenzis, E.; Lievore, E.; Turetti, M.; Gallioli, A.; Galassi, B.; Boeri, L.; Montanari, E. Ureteral Stent and Percutaneous Nephrostomy in Managing Malignant Ureteric Obstruction of Gastrointestinal Origin: A 10 Years’ Experience. Gastrointest. Disord. 2020, 2, 456-468. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040041

AMA Style

De Lorenzis E, Lievore E, Turetti M, Gallioli A, Galassi B, Boeri L, Montanari E. Ureteral Stent and Percutaneous Nephrostomy in Managing Malignant Ureteric Obstruction of Gastrointestinal Origin: A 10 Years’ Experience. Gastrointestinal Disorders. 2020; 2(4):456-468. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040041

Chicago/Turabian Style

De Lorenzis, Elisa, Elena Lievore, Matteo Turetti, Andrea Gallioli, Barbara Galassi, Luca Boeri, and Emanuele Montanari. 2020. "Ureteral Stent and Percutaneous Nephrostomy in Managing Malignant Ureteric Obstruction of Gastrointestinal Origin: A 10 Years’ Experience" Gastrointestinal Disorders 2, no. 4: 456-468. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord2040041

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop